Efficacy of Dexamethasone or Adrenaline in Inferior Alveolar Nerve Block

Model scores of the 29,894 trials active now.

Model score 5% for any early termination, 2% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 14% of the time (741 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2021-02-28. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Accepts healthy volunteers: Yes (lowers risk) · Who can join
• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: dexamethasonetypepurposestudy iseffective
  Phrases that lowered it: painand safetypatientsevaluate theinjection
• Sponsor's past termination rate: 0% (lowers risk) · Sponsor's track record
• Phase: 3 (lowers risk) · Design
• Responsible party: principal investigator (lowers risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Primary purpose: supportive care (lowers risk) · Design
• Has a data monitoring committee: Yes (raises risk) · Design
• Drug's FAERS reports with a death: 18.6% (lowers risk) · Drug's FDA history
• Design: parallel (raises risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Disease area, cancer: No (lowers risk) · Disease area
• Drug's FAERS reports before start: 185285 (lowers risk) · Drug's FDA history
• Trials the sponsor started in the prior 2 years: 2 (raises risk) · Sponsor's track record
• Maximum age: 60 (lowers risk) · Who can join
• Number of arms: 2 (raises risk) · Design
• Sponsor's past trials: 5 (lowers risk) · Sponsor's track record
• Blinding: double (raises risk) · Design
• Collaborators: 1 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Dexmedetomidine Versus Magnesium Sulphate Added to Bupivacaine in Infraorbital Nerve Block for Perioperative Analgesia in Paediatric Patients for Cleft Lip Surgery NCT05624151 · started 2022 · scored riskier than 11% of active trials completed
• Effect of Premedication on Success of Inferior Alveolar Nerve Block Injection NCT02601911 · started 2015 · scored riskier than 11% of active trials completed
• Perineural Low-dose Dexamethasone Added to Infraclavicular Block Anesthesia NCT02698995 · started 2015 · scored riskier than 7% of active trials completed
• CT Evaluating the Efficacy of Pre-incisional Local Analgesia With Ropivacaine + Dexamethasone in Pain Management After Tonsillectomy NCT05504967 · started 2020 · scored riskier than 8% of active trials completed
• Effect of Lidocaine/Dexamethasone on the Success of IANB NCT03531970 · started 2016 · scored riskier than 5% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.